C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.
C4X Discovery continues to advance its in-house pipeline that is primarily focussed on the high value therapeutic areas of immunology/inflammation, neurology/neurodegeneration and cancer (including immuno-oncology) as these areas are subject to the most significant R&D licensing activity in the pharmaceutical sector (BIO Industry Analysis, “Emerging, Therapeutic Company Investment and Deal Trends”, May 2018).
1. 4 additional early discovery programmes currently paused due to insufficient chemical opportunity
2. Disease targets with high commercial opportunity and partnering potential against which C4X’s proprietary drug discovery technologies can provide a competitive advantage in development.